Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...

Tandem Diabetes Care ( TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

The "Rapid Acting Insulin Market Report, Forecast by Product, Indication, Distribution Channel, Countries and Company ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Arecor Presents Positive Data From Phase I Clinical Trial Of Ultra-Concentrated Ultra-Rapid Acting Insulin At278 In ...

Type 2 diabetes is characterized by the body's inability to use insulin effectively. Insulin is a hormone that helps regulate metabolism properly. The condition is the most common type of ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Rapid Acting Insulin market Report, Forecast by Product, Indication, Distribution Channel, Countries and Company ...

“The QWINT studies represent a significant advancement in diabetes management, particularly with the development of a weekly insulin injection,” Tal told Healthline. “This long-acting ...